[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$flbEZ8T6WgWj6UkY-Yw7wRxOPK4WNOWsmZjBnKkGJmRo":8,"$fbbvBJ8yiz6L7x6OBqjKcj_Ua77wQn0TN_1Z7Tb8yjLc":55,"$fPUVjsVrdJ_Nauhtb463kX0uBc6JG5rTouVqi1TziXAo":59},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":54},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"hospital":17,"department":18,"postsTitle":19,"materialTotal":20,"videoTotal":21,"isConcern":7,"title":22,"coverVertical":23,"coverAcross":24,"content":25,"description":26,"views":27,"likes":21,"isThumbsUp":7,"isCollection":7,"collections":21,"createTime":28,"seoTitle":22,"seoKeywords":29,"seoDescription":30,"shelvesTime":31,"version":32,"menus":33,"menuId":35,"type":42,"quality":53,"commentCount":21,"isComment":42},57266,867568,[],"https://ystcdn.venuertc.com/learnMaterial/ystApp//Qwz6GyCWTi4XHRajDQhvP0c86fSiOy65.png","李文旭","温州老年病医院","肿瘤科","主治医师",317,0,"卵巢癌复发与腹膜转移：化疗方案的实用药品指南","","https://ystcdn.venuertc.com/venue/AI/84605eba-bd80-4102-9951-1bbeffb8970c.jpg","\u003C!-- 卵巢癌复发及腹膜转移化疗药品实用指南，专注药物知识，不谈疾病本身 -->\n\n\u003Cdiv class=\"oc_chemotherapy-container\">\n  \u003Ch1 id=\"material_title\" class=\"oc_chemotherapy-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">卵巢癌复发与腹膜转移：化疗方案的实用药品指南\u003C/h1>\n  \n  \u003Cdiv class=\"oc_chemotherapy-intro\">\n    说起紫杉醇和铂类药物，它们在联合化疗中有着非常广泛的应用。其实，这两种药品，外加部分抗血管生成靶向药，现在已被大量用于化疗治疗中。很多朋友比较关注药物怎么用、用多少、什么人不能用，以及怎样识别副作用。本文就为你梳理7个关键用药细节，希望你用得明明白白，少走弯路。⚗️\n  \u003C/div>\n\n  \u003C!-- 01 药品机制及分子作用简明科普 -->\n  \u003Csection class=\"oc_chemotherapy-section\" style=\"background: linear-gradient(120deg, #f6f6ff 0%, #f8fafc 100%)\">\n    \u003Ch2 class=\"oc_chemotherapy-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">🔬 01 三大类化疗与靶向药：作用机制简析\u003C/h2>\n    \u003Cdiv class=\"oc_chemotherapy-content\">\n      \u003Cul>\n        \u003Cli>\u003Cb>紫杉醇类\u003C/b>（如紫杉醇、白蛋白结合型紫杉醇）：通过稳定微管结构，阻断细胞分裂，从而抑制肿瘤细胞增殖。\u003C/li>\n        \u003Cli>\u003Cb>铂类药物\u003C/b>（如顺铂、卡铂）：在细胞DNA内形成交联，阻碍DNA复制，导致肿瘤细胞死亡。\u003C/li>\n        \u003Cli>\u003Cb>抗血管生成靶向药\u003C/b>（常用为贝伐珠单抗）：主要阻断肿瘤血管新生，使肿瘤因无法获得充足养分而受抑制。\u003C/li>\n      \u003C/ul>\n      \u003Cdiv class=\"oc_chemotherapy-tip\">\n        化疗药品的核心机制是针对细胞分裂、DNA修复和肿瘤微环境干预。掌握这一点，有助于理解副作用产生的原因及药物联合的必要性。\n      \u003C/div>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 02 常用剂型与规格：选择与使用要点 -->\n  \u003Csection class=\"oc_chemotherapy-section\" style=\"background: linear-gradient(120deg, #f1f7fa 0%, #f7f7fb 100%)\">\n    \u003Ch2 class=\"oc_chemotherapy-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">📦 02 剂型与规格怎么选？\u003C/h2>\n    \u003Cdiv class=\"oc_chemotherapy-content\">\n      \u003Col>\n        \u003Cli>\n          \u003Cb>紫杉醇类\u003C/b>：\n          \u003Cul>\n            \u003Cli>常用剂型为注射液，浓度如30mg/5ml、100mg/16.7ml等。\u003C/li>\n            \u003Cli>白蛋白结合型紫杉醇为一种新型制剂，溶剂成分不同，适合溶剂过敏史患者。\u003C/li>\n          \u003C/ul>\n        \u003C/li>\n        \u003Cli>\n          \u003Cb>铂类药物\u003C/b>：\n          \u003Cul>\n            \u003Cli>顺铂、卡铂均为注射剂，规格如50mg、100mg等。\u003C/li>\n          \u003C/ul>\n        \u003C/li>\n        \u003Cli>\n          \u003Cb>抗血管生成靶向药\u003C/b>：\n          \u003Cul>\n            \u003Cli>多为注射用单克隆抗体，规格：100mg/4ml、400mg/16ml等。\u003C/li>\n          \u003C/ul>\n        \u003C/li>\n      \u003C/ol>\n      \u003Cdiv class=\"oc_chemotherapy-tip\">\n        注射剂使用时一般需要专业医护操作；不同规格剂量明确，务必严格按照医嘱调整。若首次用药需试针或加强监测，不可自调用量！\n      \u003C/div>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 03 正确用法用量：关键细节说明 -->\n  \u003Csection class=\"oc_chemotherapy-section\" style=\"background: linear-gradient(120deg, #f9f9f3 0%, #f5f8f7 100%)\">\n    \u003Ch2 class=\"oc_chemotherapy-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">⏱️ 03 如何用药？时间与用量指南\u003C/h2>\n    \u003Cdiv class=\"oc_chemotherapy-content\">\n      \u003Cp>\n        这类化疗药品普遍采用周期性静脉滴注，典型疗程每3周或4周为1周期。重要细节如下：\n      \u003C/p>\n      \u003Cul>\n        \u003Cli>\u003Cb>紫杉醇类\u003C/b>：最常用的剂量为每平方米体表面积135~175mg，每次输注时间约3小时。\u003C/li>\n        \u003Cli>\u003Cb>卡铂\u003C/b>：剂量依据AUC（药物暴露量）和体表面积计算，具体要由医生根据肾功能等个体化调整。\u003C/li>\n        \u003Cli>\u003Cb>顺铂\u003C/b>：剂量通常在每平方米体表面积70~100mg。\u003C/li>\n        \u003Cli>\u003Cb>靶向药物\u003C/b>：如贝伐珠单抗，首剂15mg/kg，后续可根据疗效与耐受调整，常见为每3周一次。\u003C/li>\n      \u003C/ul>\n      \u003Cdiv class=\"oc_chemotherapy-tip\">\n        正确做法：务必遵循医嘱周期与总疗程，定时复查血象和肝肾功能，不要随意更改用药天数或剂量。\n      \u003C/div>\n      \u003Cdiv class=\"oc_chemotherapy-case\">\n        临床上有位44岁女性患者，联合使用紫杉醇与卡铂化疗，通过权威药师和医生的配合指导，顺利完成足量疗程，有效规避了剂量遗漏和过量问题。\n      \u003C/div>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 04 联合用药与支持用药：提升疗效防副作用 -->\n  \u003Csection class=\"oc_chemotherapy-section\" style=\"background: linear-gradient(120deg, #f8f7ff 0%, #f4f7fa 100%)\">\n    \u003Ch2 class=\"oc_chemotherapy-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">🌱 04 联合方案与支持用药该怎么配合？\u003C/h2>\n    \u003Cdiv class=\"oc_chemotherapy-content\">\n      \u003Cul>\n        \u003Cli>\n          \u003Cb>合理联合\u003C/b>：紫杉醇类+铂类为主流化疗组合，可根据不同方案选择靶向药协同（如贝伐珠单抗）。\n        \u003C/li>\n        \u003Cli>\n          \u003Cb>支持用药\u003C/b>：常用止吐药（如昂丹司琼）、护肝护肾药，预防副作用出现。\n        \u003C/li>\n        \u003Cli>\n          \u003Cb>糖皮质激素预处理\u003C/b>：例如地塞米松，提前应用有助减少紫杉醇引发的过敏反应。\u003C/li>\n      \u003C/ul>\n      \u003Cdiv class=\"oc_chemotherapy-tip\">\n        正确做法：配合支持用药可明显减轻常见副作用，提高治疗依从性；切勿自行停服或增减辅助药物。\n      \u003C/div>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 05 药物相互作用防范：安全组合用药关键 -->\n  \u003Csection class=\"oc_chemotherapy-section\" style=\"background: linear-gradient(120deg, #f6faf9 0%, #f3f6fa 100%)\">\n    \u003Ch2 class=\"oc_chemotherapy-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">⚡ 05 药物相互作用：严格防范不当组合\u003C/h2>\n    \u003Cdiv class=\"oc_chemotherapy-content\">\n      \u003Cul>\n        \u003Cli>\n          \u003Cb>紫杉醇类\u003C/b>：禁与某些抗真菌药（伊曲康唑）、某些抗生素（红霉素）同时使用，否则代谢抑制，毒性增加。\n        \u003C/li>\n        \u003Cli>\n          \u003Cb>卡铂/顺铂\u003C/b>：不建议与氨基糖苷类抗生素、大剂量呋塞米合用，以防肾毒性或耳毒性叠加。\n        \u003C/li>\n        \u003Cli>\n          \u003Cb>靶向药物\u003C/b>：谨慎与抗凝药、激素类药物同用，防止出血风险升高。\n        \u003C/li>\n      \u003C/ul>\n      \u003Cdiv class=\"oc_chemotherapy-tip\">\n        正确做法：掌握用药间隔，避免与上述药物重复叠加。如有多重用药需求，优先让专业药师评估调整组合方案。\n      \u003C/div>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 06 特殊人群与剂量调整：每个人都得量身定制 -->\n  \u003Csection class=\"oc_chemotherapy-section\" style=\"background: linear-gradient(120deg, #f7f8f4 0%, #f1f7f5 100%)\">\n    \u003Ch2 class=\"oc_chemotherapy-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">👪 06 特殊人群用药：如何调整？\u003C/h2>\n    \u003Cdiv class=\"oc_chemotherapy-content\">\n      \u003Cul>\n        \u003Cli>\u003Cb>老年人\u003C/b>：器官储备降低，需酌减剂量并严密监测肝肾功能。剂量需临床个体化决策。\u003C/li>\n        \u003Cli>\u003Cb>肝肾功能不全\u003C/b>：如有肾功能损害，卡铂/顺铂剂量需下调或延长用药间隔；肝损伤者慎用紫杉醇。\u003C/li>\n        \u003Cli>\u003Cb>孕妇、哺乳期女性\u003C/b>：化疗和靶向药属禁用或需权衡利弊。\u003C/li>\n      \u003C/ul>\n      \u003Cdiv class=\"oc_chemotherapy-tip\">\n        特别提醒：不同人群的个体差别极大，千万不要照搬别人的用药经验。每次用药调整都应咨询专科医生或药剂师。\n      \u003C/div>\n      \u003Cdiv class=\"oc_chemotherapy-case\">\n        一位老年患者在化疗时调整紫杉醇剂量，效果得到保障同时副作用明显减轻，个体化药学管理很关键。\n      \u003C/div>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 07 常见不良反应与处理：做足安全防护 -->\n  \u003Csection class=\"oc_chemotherapy-section\" style=\"background: linear-gradient(120deg, #f9f6fa 0%, #f8f4f3 100%)\">\n    \u003Ch2 class=\"oc_chemotherapy-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">🚩 07 常见不良反应与应对措施\u003C/h2>\n    \u003Cdiv class=\"oc_chemotherapy-content\">\n      \u003Cul>\n        \u003Cli>\n          \u003Cb>紫杉醇类\u003C/b>：最常见的有白细胞减少、脱发、手足麻木、关节肌肉痛、过敏反应。首次输注应严密观察。出现过敏赶紧停药并按医护指导处理。\n        \u003C/li>\n        \u003Cli>\n          \u003Cb>铂类药物\u003C/b>：易致恶心呕吐、肾功能损害、电解质紊乱、听力减退。如发现耳鸣或下肢无力，及时就医评估。\u003C/li>\n        \u003Cli>\n          \u003Cb>靶向药物\u003C/b>：可能造成高血压、蛋白尿、出血，连续监测血压和尿常规很必要。\u003C/li>\n      \u003C/ul>\n      \u003Cp class=\"oc_chemotherapy-content-tip\">\n        出现异常不适时立即联系专业医护人员就诊，切勿自行停药或滥用药品。\n      \u003C/p>\n      \u003Cdiv class=\"oc_chemotherapy-case\">\n        有位患者在用卡铂后出现轻度耳鸣，医生及时调整了方案，避免了严重不良反应的发展。\n      \u003C/div>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 08 储存条件与注意要点 -->\n  \u003Csection class=\"oc_chemotherapy-section\" style=\"background: linear-gradient(120deg, #f5f7f9 0%, #f8faff 100%)\">\n    \u003Ch2 class=\"oc_chemotherapy-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">🗃️ 08 储存方法与有效期\u003C/h2>\n    \u003Cdiv class=\"oc_chemotherapy-content\">\n      \u003Cul>\n        \u003Cli>大部分化疗、靶向药均需密闭、避光贮存，温度控制在2-8℃（部分制剂可室温）。\u003C/li>\n        \u003Cli>开封后按说明书规定时间使用，静脉制剂应立即配制并尽快输注。\u003C/li>\n        \u003Cli>过期药品需妥善交由医疗机构专业回收，不得自行处理或继续使用。\u003C/li>\n      \u003C/ul>\n      \u003Cdiv class=\"oc_chemotherapy-tip\">\n        正确做法：严格遵守药品包装要求，避免高温、潮湿或冷冻。自备药品时避免私自拆包或混合存放。\n      \u003C/div>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 09 漏服、过量与急救 -->\n  \u003Csection class=\"oc_chemotherapy-section\" style=\"background: linear-gradient(120deg, #fcfcf8 0%, #f5f7f3 100%)\">\n    \u003Ch2 class=\"oc_chemotherapy-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">⏳ 09 漏服与过量处理方案\u003C/h2>\n    \u003Cdiv class=\"oc_chemotherapy-content\">\n      \u003Cul>\n        \u003Cli>化疗药品偶尔延期应立即报告医生，切不可自行补加或自行调整下次剂量。\u003C/li>\n        \u003Cli>如误用过量，第一时间就医，携带剩余药品及药品包装以便医护判断用药总量。\u003C/li>\n      \u003C/ul>\n      \u003Cp class=\"oc_chemotherapy-content-tip\">\n        紧急措施以停止用药和对症支持治疗为主，切勿自行诱导呕吐或用民间偏方处理。\n      \u003C/p>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 10 结语：牢牢记住这几点 -->\n  \u003Csection class=\"oc_chemotherapy-section\" style=\"background: linear-gradient(120deg, #f8fbfd 0%, #f2f7fa 100%)\">\n    \u003Ch2 class=\"oc_chemotherapy-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">🔖 总结与提醒\u003C/h2>\n    \u003Cdiv class=\"oc_chemotherapy-content\">\n      \u003Cdiv class=\"oc_chemotherapy-tip\">\n        紫杉醇类、铂类、抗血管生成靶向药在规范化疗和腹膜转移方案中占据核心地位。用药时重点记住这几条：\u003Cbr>\n        \u003Cb>1. 一定遵循医嘱剂量与用法。\u003C/b>\u003Cbr>\n        \u003Cb>2. 规范组合与副作用监测同等重要。\u003C/b>\u003Cbr>\n        \u003Cb>3. 出现不良反应或特殊情况优先让医师、药师参与调整。\u003C/b>\n      \u003C/div>\n      \u003Cp>\n        实际治疗中，每个人的体质和用药反应差异很大，不可只凭经验调整。当心药物间的相互作用和特殊人群的剂量变化。安全、科学地用药永远是第一位！\n      \u003C/p>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 文献引用 -->\n  \u003Csection class=\"oc_chemotherapy-section\" style=\"background: linear-gradient(120deg, #f7f7fa 0%, #f0f8ff 100%)\">\n    \u003Ch2 class=\"oc_chemotherapy-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">📚 参考文献\u003C/h2>\n    \u003Cdiv class=\"oc_chemotherapy-content\">\n      \u003Col>\n        \u003Cli>\n          Pujade-Lauraine, E., Ledermann, J. A., Selle, F., et al. (2014). Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. \u003Ci>The Lancet Oncology\u003C/i>, 18(9), 1274-1284.\n        \u003C/li>\n        \u003Cli>\n          Bookman, M. A., Brady, M. F., McGuire, W. P., et al. (2009). Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the Gynecologic Cancer InterGroup. \u003Ci>Journal of Clinical Oncology\u003C/i>, 27(9), 1419-1425.\n        \u003C/li>\n        \u003Cli>\n          Aghajanian, C., Blank, S. V., Goff, B. A., et al. (2012). OCEANS: A randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. \u003Ci>Journal of Clinical Oncology\u003C/i>, 30(17), 2039-2045.\n        \u003C/li>\n        \u003Cli>\n          Markman, M. (2022). UpToDate: \"Chemotherapy and targeted therapy for the management of recurrent and resistant ovarian cancer.\" Last updated March 2022.\n        \u003C/li>\n      \u003C/ol>\n    \u003C/div>\n  \u003C/section>\n\u003C/div>\n\n\u003Cstyle>\n/* 独立的全局样式命名，避免污染其他页面 */\n\n.oc_chemotherapy-container {\n  max-width: 800px;\n  margin: 30px auto;\n  background: #fff;\n  border-radius: 18px;\n  box-shadow: 0 8px 36px rgba(80,90,110,0.10);\n  padding: 40px 34px 32px 34px;\n  font-family: 'Segoe UI', 'Microsoft Yahei', Arial, sans-serif;\n  color: #273143;\n  font-size: 17px;\n  line-height: 1.85;\n}\n.oc_chemotherapy-title {\n  font-size: 2.4em;\n  color: #2d4486;\n  margin-bottom: 38px;\n  font-weight: bold;\n  border-left: 7px solid #b1bbfa;\n  padding-left: 20px;\n  line-height: 1.25;\n  letter-spacing: 2px;\n}\n.oc_chemotherapy-intro {\n  background: linear-gradient(100deg, #f9faff 60%, #e9f1fa 100%);\n  padding: 20px 24px 15px 20px;\n  margin-bottom: 28px;\n  border-radius: 12px;\n  box-shadow: 0 3px 12px rgba(165,178,230,0.06);\n  font-size: 1.12em;\n  font-weight: 500;\n}\n.oc_chemotherapy-section {\n  margin-bottom: 34px;\n  padding: 28px 22px 19px 22px;\n  border-radius: 14px;\n  box-shadow: 0 2px 8px rgba(186, 201, 220, 0.05);\n}\n.oc_chemotherapy-subtitle {\n  font-size: 1.32em;\n  color: #3969b0;\n  margin-bottom: 16px;\n  line-height: 1.25;\n  letter-spacing: 1px;\n  font-weight: 600;\n  background: rgba(173, 186, 255, 0.11);\n  border-radius: 7px;\n  padding: 8px 18px;\n  display: inline-block;\n}\n.oc_chemotherapy-content {\n  font-size: 1em;\n  color: #303548;\n}\n.oc_chemotherapy-content ul,\n.oc_chemotherapy-content ol {\n  margin: 10px 0 10px 26px;\n  padding: 0;\n}\n.oc_chemotherapy-content ul li,\n.oc_chemotherapy-content ol li {\n  margin-bottom: 8px;\n  font-size: 1em;\n}\n.oc_chemotherapy-tip {\n  background: linear-gradient(140deg, #e9f7f4 94%, #b6e6e5 8%);\n  padding: 12px 20px;\n  border-radius: 8px;\n  margin-top: 15px;\n  margin-bottom: 5px;\n  font-size: 1em;\n  color: #247070;\n  font-weight: 500;\n  box-shadow: 0 2px 9px rgba(90,164,140,0.07);\n}\n.oc_chemotherapy-case {\n  background: linear-gradient(90deg, #faf4e3 80%, #fbe8c4 100%);\n  padding: 10px 16px;\n  border-left: 4px solid #fac98f;\n  border-radius: 7px;\n  font-size: 0.98em;\n  margin: 13px 0 4px 0;\n  color: #c08821;\n}\n.oc_chemotherapy-content-tip {\n  color: #ba2732;\n  font-size: 1.02em;\n  background: linear-gradient(90deg, #fff0f0 90%, #ffecec 100%);\n  padding: 8px 16px;\n  border-radius: 6px;\n  margin: 14px 0 8px 0;\n}\n@media (max-width: 1000px) {\n  .oc_chemotherapy-container {\n    padding: 23px 4% 12px 4%;\n  }\n  .oc_chemotherapy-title {\n    font-size: 1.3em;\n    padding-left: 13px;\n  }\n}\n\u003C/style>\n\n","\u003C!-- 卵巢癌复发及腹膜转移化疗药品实用指南，专注药物知识，不谈疾病本身 -->\n\n\u003Cdiv class=\"oc_chemotherapy-container\">\n  \u003Ch1 id=\"materia",540,"2025-08-08 15:52:23","卵巢癌, 紫杉醇, 铂类药物, 化疗, 抗血管生成靶向药, 副作用, 用药指南, 药物相互作用","了解卵巢癌复发与腹膜转移的化疗药物使用细节，掌握紫杉醇、铂类及靶向药物的用法与注意事项，确保安全有效！","2025-08-08 23:06:00",2,[34],{"menuId":35,"menuName":36,"parentId":21,"orderNum":32,"path":37,"component":38,"isFrame":39,"isCache":40,"menuType":41,"visible":42,"status":21,"createDept":6,"remark":23,"createTime":43,"children":44,"columnImage":45,"columnLogo":46,"uncheckedLogo":6,"checkedLogo":6,"isHot":42,"isHome":21,"forceLogin":21,"color":47,"seoTitle":48,"seoKeywords":49,"seoDescription":50,"contentNum":6,"promotionalPoster":51,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":52,"routerPath":37,"componentInfo":38},"1986713082609147906","健康科普","article","/article.html","1","0","T",1,"2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","癌症肿瘤",true,{"code":9,"msg":10,"message":6,"data":56,"success":54},{"pageNo":42,"pageSize":57,"result":58,"totalSize":21},10,[],{"code":9,"msg":10,"message":6,"data":60,"success":54},{"authors":61,"appraiseDimensionScoresVos":62},[],[]]